United States set
Menu Shopping cart $0 Search
Distributed product

QuickZyme Human MMP-9 Activity Assay Kit 96-Assays

  • Regulatory status:RUO
  • Type:ELISA
  • Other names:Matrix Metalloproteinase-9, MMP9
  • Species:Human
Cat. No. Size Price

Discount QZBMMP9H 96 wells (1 kit) $1242,89
PubMed Product Details
Technical Data




The QuickZyme human MMP-9 activity assay enables you to specifically measure in biological samples both active human MMP-9, as well as (pro)MMP-9 which is activated on the plate by APMA. It can be used for the measurement of MMP-9 activity in various biological samples, such as conditioned culture media, tissue homogenates, serum, plasma and urine.


Serum, Urine, Plasma, Tissue homogenates, Cell culture conditioned medium

Sample Requirements

10 - 100 µl


On dry ice. Upon receipt, store the product at the temperature recommended below.


Unopened kit: Store at -20°C, except for the standard, this vial should be stored at -70°C. Do not use kit, or individual kit components past kit expiration date.

Opened kit / reconstituted reagents: Please refer to kit manual.

Calibration Range

0 - 16 ng/ml

Limit of Detection

0.1 ng/ml (1 hr incubation)

0.005 ng/ml (4 hr incubation)



  • Measures endogenous active MMP-9 ( naturally occurring ) or total active MMP-9 ( following activation with APMA ).

  • Samples: conditioned cell culture medium, serum, plasma, urine, synovial fluid and tissue homogenates.

  • Quantitative.

  • Range: 0.5 to 16 ng/ml (1 h incubation with detection reagent), 0.01-1 ng/ml (4 h incubation with detection reagent).

  • Sensitivity: 0.005 ng/ml.

  • Ease-of-use: Equivalent to ELISA.

Research topic

Bone and cartilage metabolism, Cardiovascular disease, Extracellular matrix, Immune Response, Infection and Inflammation, Neural tissue markers, Oncology, Others, Pulmonary diseases


Matrix metalloproteinases (MMPs) are a family of enzymes that function in the remodeling of extracellular matrix proteins. They are essential for various normal physiological processes such as embryonic development, morphogenesis, reproduction tissue resorption and tissue remodeling. They also play a role in a number of pathological processes such as inflammation, arthritis, cardiovascular diseases, fibrosis and cancer. Regulation of MMPs is carried out at various levels. Expression of latent MMPs is regulated at the level of transcription, whereas the proteolytic activity is controlled by specific activation of proMMPs, and by MMP-specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs) or general circulatory inhibitors, such as α2macroglobulin. The MMPs can be grouped according to their domain structure into collagenases, gelatinases, stromelysins, membrane type MMPs and matrilysins. MMP-9 (also known as type neutrophil gelatinase, IV collagenase, Gelatinase B; EC has a broad range of substrate specificity for denatured collagens (gelatins), native collagens (types IV, V and XI), as well as elastin. Human MMP-9 has a Mw of 92 kDa (pro-form) and 82 kDa (active form). The activity is dependent on Zn2+ and Ca2+. MMP-9 is secreted as proMMP-9, and can be activated in vitro by organo mercurial compounds such as p-aminophenyl mercuric acetate (APMA). MMP-9 is produced by a variety of cell types including monocytes, macrophages, fibroblasts, neutrophils, osteoclasts, chondrocytes, keratinocytes, endothelial and epithelial cells. The QuickZyme human MMP-9 activity assay enables you to specifically measure in biological samples both active human MMP-9, as well as (pro)MMP-9 which is activated on the plate by APMA. It can be used for the measurement of MMP-9 activity in various biological samples, such as conditioned culture media, tissue homogenates, serum, plasma and urine.

Summary References (23)

References to MMP-9

  • Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003 Jan;28 (1):12-24
  • Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003 Nov;253 (1-2):269-85
  • Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol. 2002;18 (1):51-61
  • Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res. 2001 Aug 3;89 (3):201-10
  • Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 2003 Jun-Sep;22 (2-3):153-66
  • Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, Alishekevitz D, Bertolini F, Shaked Y. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res. 2011 Nov 15;71 (22):6986-96
  • Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000 Sep;115 (3):337-44
  • John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7 (1):14-23
  • Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest. 2001 Feb;48 (1-2):31-43
  • Kelly EA, Jarjour NN. Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med. 2003 Jan;9 (1):28-33
  • Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004 May;50 (2):87-100
  • Matusiewicz M, ORCID: 0000-0003-4624-0109, Neubauer K, ORCID: 0000-0003-3650-9311, Mierzchala-Pasierb M, ORCID: 0000-0001-9640-4883, Gamian A, Krzystek-Korpacka M. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014;2014:643645
  • Nakada M, Okada Y, Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci. 2003 Jan 1;8:e261-9
  • Niimi T, Keck-Waggoner CL, Popescu NC, Zhou Y, Levitt RC, Kimura S. UGRP1, a uteroglobin/Clara cell secretory protein-related protein, is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor. Mol Endocrinol. 2001 Nov;15 (11):2021-36
  • Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci. 2002 Aug;3 (4):409-21
  • Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2003 Dec;2 (12):747-56
  • Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001 Jun;69 (6):851-9
  • Opstad TB, Pettersen AA, Arnesen H, Seljeflot I. The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS One. 2013;8 (9):e74498
  • Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe?. Breast Dis. 2004;20:145-53
  • Sellebjerg F, Sorensen TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull. 2003 Aug 15;61 (3):347-55
  • Shah BH, Catt KJ. Matrix metalloproteinases in reproductive endocrinology. Trends Endocrinol Metab. 2004 Mar;15 (2):47-9
  • Snitker S, Xie K, Ryan KA, Yu D, Shuldiner AR, Mitchell BD, Gong DW. Correlation of circulating MMP-9 with white blood cell count in humans: effect of smoking. PLoS One. 2013;8 (6):e66277
  • Thompson MM, Squire IB. Matrix metalloproteinase-9 expression after myocardial infarction: physiological
Related Products Docs